Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Leukocyte Adhesion Deficiency Management Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The leukocyte adhesion deficiency management market size has experienced significant expansion in recent years. It is anticipated to increase from $8.59 billion in 2025 to $9.16 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.6%. The historical growth can be linked to factors such as limited therapeutic alternatives for rare immunodeficiency disorders, elevated infection-related mortality rates, reliance on antimicrobial treatments, inadequate awareness of leukocyte adhesion deficiency, and restricted access to advanced transplantation facilities.
The market for managing leukocyte adhesion deficiency is projected to experience robust expansion over the coming years, with forecasts indicating it will reach $12.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. Key drivers for this growth during the projection period include progress in stem cell transplantation methods, increased access to genetic screening, heightened investment in research for rare diseases, a rise in personalized immunotherapy adoption, and the proliferation of specialized immunology treatment facilities. Significant trends anticipated in the forecast timeframe encompass the broader application of hematopoietic stem cell transplantation, an uptake in gene-based diagnostic tests, an increase in prophylactic immunoglobulin therapy usage, a greater emphasis on preventing early infections, and breakthroughs in targeted immunomodulatory therapies.
Get A Free Sample Report With In-Depth Market Insights:
Leukocyte Adhesion Deficiency Management Market Demand Drivers: What’s Powering Industry Growth?
The increasing incidence of primary immunodeficiency is expected to propel the growth of the leukocyte adhesion deficiency management market moving forward. Primary immunodeficiency (PID) refers to a group of inherited conditions that compromise the body’s immune system, making individuals more susceptible to infections and illnesses due to defects in their immune responses. Managing leukocyte adhesion deficiency benefits primary immunodeficiency by advancing the understanding of immune system disorders and potentially leading to improved diagnostic tools and therapies for both conditions. For example, in April 2023, according to the Peace Hospital, an India-based multi-specialty hospital, data collected from World Primary Immunodeficiency (WPI) Awareness Week 2023 indicates that primary immunodeficiency (PI) impacts an estimated 60 lakh people globally, with 70% to 90% of individuals having undiagnosed primary immunodeficiency. Consequently, the rising prevalence of primary immunodeficiency will drive the expansion of the leukocyte adhesion deficiency management market.
Leukocyte Adhesion Deficiency Management Market Segment Outlook: Which Categories Are Growing Fastest?
The leukocyte adhesion deficiency management market covered in this report is segmented –
1) By Treatment: Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation
2) By Diagnosis: Blood Test, Genetic Testing
3) By End-Users: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Hematopoietic Stem Cell Transplantation: Related Donor Transplant, Unrelated Donor Transplant
2) By Recombinant Human Interferon-Gamma Treatment: Standard Dosing, Customized Dosing
3) By Prophylactic Immunoglobulin Therapy: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)
4) By Antimicrobial Therapy: Antibiotics, Antifungal Treatments
5) By Prophylactic Therapy: Vaccination Strategies, Infection Prevention Protocols
6) By Fucose Supplementation: Oral Supplements, Intravenous Supplements
Leukocyte Adhesion Deficiency Management Market Innovation Trends: What Developments Are Reshaping The Industry?
Major companies within the leukocyte adhesion deficiency management market are developing lentiviral vector-based gene therapy technology to enhance targeted treatments and improve patient outcomes. This particular gene therapy offers a precise method in leukocyte adhesion deficiency management by delivering corrective genes directly into cells, potentially restoring immune function. For instance, in February 2024, Rocket Pharmaceuticals, a US-based biotechnology company, launched kresladi (marnetegragene autotemcel) for the treatment of severe leukocyte adhesion deficiency-I (LAD-I). In a Phase 1/2 study, it achieved 100% survival at 12 months, considerably reducing infections and alleviating symptoms. Kresladi presents a pioneering option in the LAD management market, addressing significant unmet needs.
Leukocyte Adhesion Deficiency Management Market Leading Companies And Competitive Benchmarking
Major companies operating in the leukocyte adhesion deficiency management market are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Gilead Sciences Inc, Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd, Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc, Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.
View The Full Leukocyte Adhesion Deficiency Management Market Report:
Leukocyte Adhesion Deficiency Management Market Top Region By Revenue And Market Share
North America was the largest region in the leukocyte adhesion deficiency management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukocyte adhesion deficiency management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









